Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is a prescription injectable solution containing human coagulation factor VIII and von Willebrand factor. It is supplied as a sterile intravenous preparation used to replace deficient clotting proteins in patients with bleeding disorders. The product is manufactured for the European market and is classified as a coagulation factor concentrate. Haemate P is administered under medical supervision to support normal clot formation and platelet adhesion.

Haemate P is indicated for the management of several inherited bleeding disorders where factor VIII and von Willebrand factor are deficient or dysfunctional.

- Treatment of acute bleeding episodes in patients with hemophilia A. - Routine prophylaxis to prevent spontaneous bleeds in hemophilia A. - Management of von Willebrand disease types 1, 2, and 3, including on‑demand therapy for bleeding. - Surgical or invasive procedure support to maintain hemostasis in affected individuals. - Use in combination with other hemostatic agents when clinically appropriate.

Adverse reactions reported with Haemate P vary in frequency and severity.

Common: - Injection site pain or erythema. - Headache. - Fever or chills. - Nausea or vomiting. - Transient increase in liver enzymes.

Serious: - Development of inhibitors (antibodies) to factor VIII. - Anaphylactic or severe allergic reactions. - Thromboembolic events. - Hemolysis. - Disseminated intravascular coagulation (DIC).

Before initiating Haemate P therapy, clinicians should evaluate several safety considerations.

- Assess patient history for previous inhibitors to factor VIII. - Monitor for signs of allergic reactions during and after infusion. - Evaluate liver and renal function prior to treatment. - Use caution in patients with a history of thrombosis or cardiovascular disease. - Adjust dose in pediatric patients and those with low body weight. - Avoid use in individuals with known hypersensitivity to any component of the product. - Ensure proper storage and handling to maintain product stability.

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid: - Concurrent use of other factor concentrates without medical supervision. - High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk. - Antifibrinolytic agents unless specifically indicated.

Use with caution: - Immunosuppressive therapies that may alter inhibitor development. - Warfarin or other anticoagulants; monitor coagulation parameters closely. - Desmopressin (DDAVP) when combined with Haemate P for von Willebrand disease.